Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.
Patients with HIV and AIDS are living longer because of advancements in antiretroviral therapy. These patients are often susceptible to debilitating inflammatory disorders that are refractory to standard treatment. We discuss the relationship of tumor necrosis factor-alpha and HIV and then review 27 published cases of patients with HIV being treated with tumor necrosis factor-alpha inhibitors. This review is limited because no randomized controlled trials have been performed with this patient population. Regardless, we propose that reliable seropositive patients, who are adherent to medication regimens and frequent monitoring and have failed other treatment modalities, should be considered for treatment with tumor necrosis factor-alpha inhibitors.
['Gallitano|Stephanie M|SM|', 'McDermott|Laura|L|', 'Brar|Kanwaljit|K|', 'Lowenstein|Eve|E|']
D000163:Acquired Immunodeficiency Syndrome D000068879:Adalimumab D000328:Adult D000368:Aged D061067:Antibodies, Monoclonal, Humanized D015496:CD4-Positive T-Lymphocytes D018572:Disease-Free Survival D000068800:Etanercept D005260:Female D015658:HIV Infections D006801:Humans D000069285:Infliximab D008297:Male D008875:Middle Aged D008991:Monitoring, Physiologic D011379:Prognosis D058996:Quality Improvement D016032:Randomized Controlled Trials as Topic D012720:Severity of Illness Index D016019:Survival Analysis D016896:Treatment Outcome D014409:Tumor Necrosis Factor-alpha D055815:Young Adult
HIV AIDS tumor necrosis factor-alpha autoimmune disease hidradenitis suppurativa inflammatory bowel disease opportunistic infections psoriasis rheumatoid arthritis